Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease

BACKGROUND: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and ran...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Tariot, Pierre, Salloway, Steven, Yardley, Jane, Mackell, Joan, Moline, Margaret
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2012
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493328/
https://ncbi.nlm.nih.gov/pubmed/22681723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-5-283
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky